PubMed ID:
18463735
Public Release Type:
Journal
Publication Year: 2008
Affiliation: Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, Missouri, United States of America.
DOI:
https://doi.org/10.1371/journal.pone.0002123
Authors:
Aurora R,
Cannon NA,
Donlin MJ,
Fan X,
Tavis JE,
Virahep-C Study Group
Studies:
Viral Resistance to Antiviral Therapy of Chronic Hepatitis C
Pegylated interferon plus ribavirin therapy for hepatitis C virus (HCV) fails in approximately half of genotype 1 patients. Treatment failure occurs either by nonresponse (minimal declines in viral titer) or relapse (robust initial responses followed by rebounds of viral titers during or after therapy). HCV is highly variable genetically. To determine if viral genetic differences contribute to the difference between response and relapse, we examined the inter-patient genetic diversity and mutation pattern in the full open reading frame HCV genotype 1a consensus sequences.